Patients　with　diabetic　foot　ulcers　usually　suffer　from　inefficient　epithelisation　and　angiogenesis　accompanied　by　chronic　wound　healing.　Diabetic　foot　ulcers　remain　a　major　challenge　in　clinical　medicine;　however,　traditional　treatments　are　incapable　of　transdermal　drug　delivery,　resulting　in　a　low　drug　delivery　rate.　We　report　the　development　of　Ti2C3　MXenes-integrated　poly-gamma-glutamic　acid　(gamma-PGA)　hydrogel　microneedles　to　release　asiaticoside　(MN-MXenes-AS).　Asiaticoside　was　loaded　into　PGA-MXenes　hydrogel　to　facilitate　cell　proliferation　while　regulating　angiogenesis.　The　characterisation　and　mechanical　strength　of　the　microneedles　were　investigated　in　vitro,　and　the　wound-healing　efficacy　of　the　microneedles　was　confirmed　in　diabetic　mice.　MXenes　significantly　improved　the　mechanical　strength　of　microneedles,　while　gamma-PGA　hydrogels　provided　a　moist　microenvironment　for　wound　healing.　Mice　treated　with　MN-MXenes-AS　demonstrated　obvious　improvements　in　wound　healing　process.　We　successfully　fabricated　an　MXenes-integrated　microneedle　that　possesses　sufficient　rigidity　to　penetrate　the　cuticle　for　subcutaneous　drug　delivery,　thereby　accelerating　diabetic　wound　healing.　We　demonstrated　that　MN-MXenes-AS　is　effective　in　promoting　growth　both　in　vivo　and　in　vitro.　Collectively,　our　data　show　that　MN-MXenes-AS　accelerated　the　healing　of　diabetic　foot　ulcers,　supporting　the　use　of　these　microneedles　in　the　treatment　of　chronic　wounds.